Trial Profile
A Study to Evaluate the Pharmacokinetics and Glucodynamics of LY900014 Compared to Humalog Following a Single Dose in Patients With T2DM
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jun 2021
Price :
$35
*
At a glance
- Drugs Insulin lispro (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 27 May 2021 Results of pooled analysis of 4 studies (NCT02942654, NCT03286751, NCT03166124, and NCT03305822) comparing and assessing the consistency of pharmacokinetics and glucodynamics between URLi and Humalog in healthy subjects and patients with T1D or T2D, published in the Clinical Pharmacokinetics.
- 25 Sep 2020 Results of a pooled analysis of data pooled from 4 randomized trials (NCT02942654, NCT03305822, NCT03166124, NCT03286751) assessing the consistency of the pharmacokinetics and glucodynamics between URLi and Lispro in healthy subjects and patients with type 1 diabetes or type 2 diabetes, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 29 May 2020 Results published in the Clinical Pharmacokinetics